State Street vs. iShares: Which Global ETF Offers Better Value?

State Street’s SPDR Portfolio MSCI Global Stock Market ETF (SPGM) charges a lower 0.09% expense ratio versus 0.24% for iShares’ developed-markets ETF (URTH), while also offering a higher dividend yield (1.8% vs 1.4%, +0.40pp). On the risk metrics cited, both funds show similar five-year beta (SPGM 0.92 vs URTH 0.95) and max drawdown (25.9% vs 26.1%), with comparable 5-year total growth ($1,718 vs $1,729 from $1,000). The main trade-off highlighted is SPGM’s smaller AUM (~$1.9B vs ~$8.1B) versus URTH’s liquidity advantage.

Analysis

The real signal here is not “cheap ETF vs expensive ETF,” but a slow-moving shelf-war in global beta. If SPGM keeps harvesting model-portfolio and retail flows on fee alone, the first-order winner is STT’s passive franchise, while the second-order loser is the ability of high-AUM incumbents to tax investors for liquidity they may not actually need in long-only core allocations. The underlying equity impact is modest, but any incremental shift toward SPGM slightly dilutes the mega-cap concentration trade that has dominated global index ownership, which is incremental support for broader international cyclicals and EM-adjacent names over a 6-18 month horizon.

The counterpoint is that URTH’s larger asset base and deeper trading book still matter for institutions. In a drawdown or USD-strength shock, liquidity and tighter spreads can overwhelm a 15bp fee gap, so URTH may keep most of the “serious money” even if SPGM wins the price comparison on paper. That makes this more of a gradual flow story than a catalyst-driven event; there is little here that should move AAPL/MSFT/NVDA materially in the next few days.

The contrarian read is that the article may understate the opportunity cost of the extra EM and small-cap exposure inside SPGM. Those sleeves can help in a reflationary or weaker-dollar regime, but they also introduce regime risk that investors buying “cheap global equity” may not fully want. The thesis is falsified if URTH keeps outgathering SPGM despite the fee spread, or if bid-ask/liquidity costs prove large enough to negate the expense advantage for the actual buyer base.

Key Decisions for Investors

• Prefer SPGM over URTH for new strategic global-beta allocations in small to mid-sized accounts; thesis is a 12-24 month fee and breadth compounding story, with limited downside if spreads remain tight.
• For institutional-sized orders, keep URTH as the execution vehicle and avoid forcing the cheaper ETF; liquidity premium likely dominates the 15bp expense advantage in the first 1-3 months.
• Watch STT passive flows and ETF AUM growth as the cleaner tradeable angle; if SPGM keeps taking share, it is a low-beta positive for State Street’s fee pool rather than a direct equity catalyst.
• Relative-value alert: long SPGM / short URTH only on evidence of persistent flow share gains or model-portfolio adoption; otherwise the pair is too slow-moving to justify active risk.
• If risk-on broadens beyond the mega-cap cohort, reduce overexposure to AAPL/MSFT/NVDA-heavy global proxies and rotate toward broader international baskets; the benefit to SPGM would be incremental, not explosive.